Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
Study Design:
non-interventional uncontrolled observational study
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Bialystok, Polen
- Boehringer Ingelheim Investigational Site 8
-
Bialystok, Polen
- Boehringer Ingelheim Investigational Site 7
-
Bydgoszcz, Polen
- Boehringer Ingelheim Investigational Site 9
-
Bydgoszcz, Polen
- Boehringer Ingelheim Investigational Site 10
-
Chorzów, Polen
- Boehringer Ingelheim Investigational Site 11
-
Chorzów, Polen
- Boehringer Ingelheim Investigational Site 12
-
Gdañsk, Polen
- Boehringer Ingelheim Investigational Site 13
-
Gdañsk, Polen
- Boehringer Ingelheim Investigational Site 14
-
Gdañsk, Polen
- Boehringer Ingelheim Investigational Site 15
-
Kraków, Polen
- Boehringer Ingelheim Investigational Site 16
-
Kraków, Polen
- Boehringer Ingelheim Investigational Site 17
-
Poznañ, Polen
- Boehringer Ingelheim Investigational Site 18
-
Wroc£aw, Polen
- Boehringer Ingelheim Investigational Site 19
-
Wroc£aw, Polen
- Boehringer Ingelheim Investigational Site 20
-
-
-
-
-
Bacau, Rumänien
- Boehringer Ingelheim Investigational Site 50
-
Brasov, Rumänien
- Boehringer Ingelheim Investigational Site 51
-
Brasov, Rumänien
- Boehringer Ingelheim Investigational Site 52
-
Brasov, Rumänien
- Boehringer Ingelheim Investigational Site 53
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 21
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 22
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 23
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 24
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 25
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 26
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 27
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 28
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 29
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 30
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 31
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 32
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 33
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 34
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 35
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 36
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 37
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 38
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 39
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 40
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 41
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 42
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 43
-
Bucuresti, Rumänien
- Boehringer Ingelheim Investigational Site 44
-
Constanta, Rumänien
- Boehringer Ingelheim Investigational Site 46
-
Constanta, Rumänien
- Boehringer Ingelheim Investigational Site 47
-
Constanta, Rumänien
- Boehringer Ingelheim Investigational Site 48
-
Giurgiu, Rumänien
- Boehringer Ingelheim Investigational Site 45
-
Ploiesti, Rumänien
- Boehringer Ingelheim Investigational Site 49
-
-
-
-
-
Graz, Österreich
- Boehringer Ingelheim Investigational Site 6
-
Salzburg, Österreich
- Boehringer Ingelheim Investigational Site 5
-
Vienna, Österreich
- Boehringer Ingelheim Investigational Site 1
-
Vienna, Österreich
- Boehringer Ingelheim Investigational Site 2
-
Vienna, Österreich
- Boehringer Ingelheim Investigational Site 3
-
Wels, Österreich
- Boehringer Ingelheim Investigational Site 4
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion criteria:
- HIV-1 infected male and female 18 years and above;
- anti-retroviral therapy (ART) naive and pre-treated patients switching from a nevirapine immediate release or other ART.
Exclusion criteria:
Consistent with the current VIRAMUNE prolonged release SPC.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
nevirapine extended release
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Patients Reporting Non-serious Adverse Events, Serious Adverse Events, and Non-serious and Serious Adverse Events Leading to Treatment Discontinuation
Zeitfenster: up to 72 weeks
|
The primary endpoint is to evaluate the safety of a highly active antiretroviral therapy (HAART) that includes nevirapine extended release in routine clinical practice which is to assess the number of patients reporting non-serious adverse events (nSAEs), the number of patients with serious adverse events (SAE), the number of patients with non-serious adverse events leading to treatment discontinuation, and the number of patients with serious adverse events leading to discontinuation.
|
up to 72 weeks
|
|
Number of Patients Reporting Rash of Any Severity
Zeitfenster: up to 72 weeks
|
Number of patients reporting rash of any severity as adverse event
|
up to 72 weeks
|
|
Number of Patients Reporting Hepatic Events
Zeitfenster: up to 72 weeks
|
Number of patients reporting hepatic events either as adverse event (AE) or as laboratory abnormality of Grade 1 to Grade 4 in aspartate aminotransferase (AST), alanine transaminase (ALT), Gamma-Glutamyl-Transferase (Gamma-GT) and bilirubin.
|
up to 72 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Patients With Virologic Response at Week 24 (Viral Load <50 Copies/mL)
Zeitfenster: 24 weeks
|
Virologic response is defined as confirmed Human Immunodeficiency Virus (HIV) viral load of < 50 copies/mL (at two consecutive measurements after baseline) up to week 24 and without subsequent rebound or change of anti-retroviral (ARV) therapy up to week 24.
A rebound is defined as two consecutive measurements of viral load (VL) ≥ 50 copies/mL, at least two weeks apart, after two consecutive measurements of VL< 50 copies/mL.
A change of ARV therapy is defined as a permanent discontinuation of nevirapine extended release, addition of new ARV drugs, or alteration in background therapy.
A change in the background therapy due to toxicity or intolerance is not considered as treatment failure.
If no follow-up viral load was available the virologic response is Missing.
|
24 weeks
|
|
Change in CD4+ Cell Count From Baseline to Week 24
Zeitfenster: baseline and week 24
|
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 24 weeks was calculated by subtracting the baseline value from the value after 24 weeks.
Therefore, a positive change represents an increase in CD4+ cell count.
|
baseline and week 24
|
|
Change in Morisky Medication Adherence Scale Score From Baseline to 24 Weeks
Zeitfenster: baseline and week 24
|
The Morisky Medication Adherence scale (MMAS-8 scale) is a recognized indicator of medication adherence, consisting of 8 questions with a sum score ranging between 0 and 8 points.
The higher score indicates higher adherence to the prescribed therapy recommendation.
It has been agreed that the score of 8 could be categorized as having high adherence, score between 6 and 7 as medium adherence and scores of 5 and less as low adherence.
The change is presented as the score after 24 weeks minus the score at baseline.
Therefore, a positive change score reflects an improvement in the adherence.
|
baseline and week 24
|
|
Number of Patients Reporting Once Daily Nevirapine Intake More Convenient Than Twice Daily Formulation
Zeitfenster: 24 weeks
|
The number of patients reporting that they find the once daily nevirapine intake more / very much more convenient than the twice daily formulation.
|
24 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 1100.1550
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .